Ligand validation:5CU5

NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose

NAG is a Ligand Of Interest in 5CU5 designated by the RCSB

	Best-fitted instance in this entry
	Other instances in this entry

	Best-fitted instance in this entry
	Best-fitted PDB instances with same target (top 5)

	Best-fitted instance in this entry
	Best-fitted PDB instances with different target (top 5)

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
5CU5_NAG_A_1006	38%	44%	0.192	0.895	0.45	1.69	-	4	2	0	100%	0.9333
5CU5_NAG_A_1010	37%	24%	0.161	0.857	0.82	2.25	1	2	0	0	100%	0.9333
5CU5_NAG_A_1007	29%	69%	0.187	0.844	0.6	0.6	-	-	0	0	100%	0.9333
5CU5_NAG_B_1008	23%	56%	0.214	0.839	0.61	1.08	-	1	0	0	100%	0.9333
5CU5_NAG_A_1011	20%	61%	0.251	0.851	0.73	0.78	-	-	6	0	100%	0.9333
5CU5_NAG_A_1012	13%	62%	0.267	0.807	0.88	0.57	-	-	1	0	100%	0.9333
5CU5_NAG_B_1007	10%	51%	0.252	0.753	0.81	1.09	-	1	1	0	100%	0.9333
5CU5_NAG_A_1008	8%	35%	0.26	0.732	0.58	1.93	-	4	0	0	100%	0.9333
5CU5_NAG_A_1009	1%	58%	0.263	0.492	0.67	0.94	-	1	0	0	100%	0.9333
7P7P_NAG_A_1105	75%	28%	0.099	0.931	0.54	2.32	-	3	0	0	100%	0.9333
5K1V_NAG_A_1007	63%	73%	0.131	0.927	0.54	0.51	-	-	0	0	100%	0.9333
7NUP_NAG_D_1003	59%	61%	0.124	0.904	0.97	0.53	1	-	0	0	100%	0.9333
5AB0_NAG_A_1070	57%	71%	0.128	0.902	0.5	0.6	-	-	0	0	100%	0.9333
4JBS_NAG_A_1005	55%	62%	0.165	0.935	0.49	0.97	-	1	0	0	100%	0.9333
3H0C_NAG_A_794	100%	56%	0.021	0.995	0.61	1.08	-	1	0	0	100%	0.9333
5LDS_NAG_B_1007	100%	67%	0.022	0.995	0.48	0.79	-	-	0	0	100%	0.9333
5O5D_NAG_A_601	100%	65%	0.022	0.994	0.32	0.99	-	1	0	0	100%	0.9333
6MUG_NAG_G_629	100%	76%	0.022	0.994	0.35	0.58	-	-	0	0	100%	0.9333
3PPS_NAG_B_760	100%	44%	0.028	0.993	0.57	1.57	-	3	0	0	100%	0.9333

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.